| 李京秀 查理 李阳 韦国千 闫述钧 鱼龙浩 董玉梅 李馨 金恩泽 李学奇.beta受体阻断药在心力衰竭合并房颤治疗中的再评价[J].,2015,15(12):2390-2392 |
| beta受体阻断药在心力衰竭合并房颤治疗中的再评价 |
| Revaluation of the Outcome of Beta-blockers in Patients with Heart Failureand Atrial Fibrillation |
| |
| DOI： |
| 中文关键词: beta受体阻断药 心力衰竭 房颤 |
| 英文关键词: Beta-blocker Heart failure Atrial fibrillation |
| 基金项目:国家重点基础发展规划项目(973项目)（
2007CB512007） |
|
| 摘要点击次数: 711 |
| 全文下载次数: 1064 |
| 中文摘要: |
| beta肾上腺素受体阻断药被认定为心力衰竭治疗领域的里程碑，在心力衰竭指南中，茁肾上腺素受体阻断药为IA 类推荐。但
针对慢性心力衰竭的经典、大型RCT 临床试验中，房颤患者所占比率不高。新近对于心力衰竭合并房颤患者应用茁肾上腺素受
体阻断剂的死亡率和住院率进行Meta- 分析示：beta肾上腺素受体拮抗剂未见有更多临床获益（即死亡率和住院率减低水平无统计
学意义）。本文就心力衰竭定义、心力衰竭时交感神经系统激活、作用于交感神经系统的茁肾上腺素受体阻断药药理作用及分类、
beta肾上腺素受体阻断药在心力衰竭并发房颤治疗中应用地位、心力衰竭并发房颤患者应用茁肾上腺素受体阻断药存在的争议及
其原因分析进行简要综述。 |
| 英文摘要: |
| Beta-blockers act as a cornerstone therapy for patients with heart failure (HF). The use of beta-blockers is a Class IA
recommendation in current HF guidelines. However, enrollment of atrial fibrillation patients in the classic, large randomized control trials
was limited. Recently, a meta-analysis of beta-blockers in heart failure and atrial fibriallation showed that the effect of beta-blocker did
not predict a better outcome. Beta-blockade did not reduce mortality and was not associated with a reduction in hospitalization. In this
review, we introduced the definition of heart failure, the activation of sympathetic nervous system in HF, the pharmacological profiles of
beta-blockers, the first-line treatment of heart failure, and the reason for different effects of beta-blockers in heart failure patients with
atrial fibrillation. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
